Joint Corp (NASDAQ:JYNT) fell 7.3% during trading on Tuesday . The stock traded as low as $2.15 and last traded at $2.15, with a volume of 54,340 shares trading hands. The stock had previously closed at $2.32.

Several brokerages recently commented on JYNT. Zacks Investment Research upgraded Joint Corp from a “sell” rating to a “hold” rating in a report on Monday, April 25th. Feltl & Co. downgraded Joint Corp from a “strong-buy” rating to a “buy” rating in a report on Friday, June 24th. Finally, Maxim Group dropped their target price on Joint Corp from $8.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, July 1st.

The company’s 50 day moving average is $2.49 and its 200 day moving average is $3.39. The company’s market cap is $29.40 million.

Joint Corp (NASDAQ:JYNT) last posted its quarterly earnings results on Thursday, May 12th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.02. The business had revenue of $4.30 million for the quarter, compared to analyst estimates of $4.52 million. Analysts predict that Joint Corp will post ($1.01) earnings per share for the current year.

In other Joint Corp news, major shareholder Glenhill Advisors Llc purchased 80,069 shares of the company’s stock in a transaction that occurred on Friday, July 1st. The shares were purchased at an average cost of $1.97 per share, with a total value of $157,735.93. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

The Joint Corp. develops, owns, operates, supports and manages chiropractic clinics through direct ownership, management arrangements, franchising and the sale of regional developer rights throughout the United States. The Company is franchisor and operator of chiropractic clinics. The Company offers its patients the opportunity to visit its clinics without an appointment and receive prompt attention.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.